Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Is Jumping Today

By Keith Speights - Feb 16, 2021 at 12:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's continued momentum from the drugmaker's big news announced earlier this month.

What happened

Shares of Ocugen (OCGN 8.14%) were jumping 7.2% higher as of 11:28 a.m. EST after rising as much as 16.4% earlier in the day. There wasn't any news fueling the drugmaker's gain. Instead, today's move appears to stem from continued enthusiasm among investors about the prospects for COVID-19 vaccine candidate Covaxin. Ocugen announced earlier this month that it's teaming up with India-based Bharat Biotech to commercialize the vaccine in the U.S.

So what

Momentum is a law of physics that also often applies to biotech stocks such as Ocugen. Initial excitement about a stock among some investors catches the attention of other investors. As these investors scoop up shares, the cycle repeats and can create the kind of momentum we're seeing with Ocugen.

Vaccine vial with a dollar sign in it next to a syringe and another vaccine vial toppled over

Image source: Getty Images.

It's important to focus more on the business than the stock price when this scenario happens, though. Ocugen and Bharat still have several hurdles to jump before Covaxin can be commercialized in the U.S. The vaccine won emergency use authorization (EUA) in India in January, but so far no clinical studies evaluating Covaxin have been conducted in the U.S.

Ocugen currently doesn't have any products on the market. Nor does it have any candidates of its own in clinical testing. However, Ocugen's pipeline includes three preclinical programs targeting eye diseases. 

Now what

Ocugen is talking with the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) about a potential path toward securing EUA and ultimately full regulatory approval in the U.S. It's also planning to begin two phase 1/2a clinical studies of experimental gene therapy OCU400 in treating genetic eye diseases this year. Substantial progress on these efforts will probably be needed for the stock to keep its momentum going.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.39 (8.14%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.